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Decreased clearance of low-density lipoprotein in uremic patients
under dialysis treatment
SoHvI HORIucO, KAISA HUTETUNEN, and Y. ANTERO KESANIEMI
Department of Internal Medicine and Biocenter Oulu, University of Oulu, Oulu, Finland
Decreased clearance of low-density lipoprotein in urensic patients
under dialysis treatment. The clearance of low-density lipoprotein (LDL)
was studied in eleven patients on hemodialysis (HD) treatment and nine
patients on continuous ambulatory peritoneal dialysis (CAPD) treatment
and compared with the clearance of LDL in nine control subjects. The
clearance rates for LDL (fractional catabolic rate, FCR) in all the uremic
patients (FCR for LDL 0.305 0.075 pools/day, mean SD) were
significantly lower than the clearance of LDL in the control subjects (FCR
for LDL 0.376 0.045 pools/day; P = 0.01). The clearance of LDL in the
HD patients (FCR for LDL 0.334 0.066 pools/day) was only mildly
decreased in comparison to the control subjects (P = 0.122), but the
clearance of LDL in the CAPD patients was markedly decreased (FCR for
LDL 0.268 0.072 pools/day) in comparison to the control subjects (P =
0.001). The FCR for LDL among all the patients was negatively related to
the plasma total cholesterol (r =
—0.56, P = 0.01) and LDL cholesterol
concentration (r =
—0.76, P = 0.0002) and LDL apolipoprotein B
concentration (r =
—0.48, P = 0.03). In conclusion, the clearance of LDL
is decreased in uremic patients on dialysis treatment. This alteration in the
LDL metabolism of the uremic patients may contribute to their acceler-
ated atherosclerosis.
Cardiovascular disease is a major cause of morbidity and
mortality among patients with chronic renal failure [1—3]. One of
the causes for the enhanced cardiovascular problems in uremic
patients is abnormal lipoprotein metabolism [4—6]. Patients with
chronic renal failure often have hypertriglyceridemia and de-
creased high-density lipoprotein (HDL) cholesterol concentra-
tions, while the plasma total and low-density lipoprotein (LDL)
cholesterol concentrations are usually reported to be normal or
only moderately increased [4—6].
There is strong evidence suggesting that LDL metabolism plays
an important role in the development of atherosclerosis [7, 8], and
defects in either LDL particles or LDL apoB/E receptors may
cause alterations in LDL metabolism [9—16]. Earlier experiments
have shown that LDL isolated from uremic patients is altered in
such a way that its binding to the LDL apoB/E receptors [17] and
its in vivo clearance is decreased [18, 19]. Moreover, the clearance
of very low density lipoprotein (VLDL) apolipoprotein B has
been demonstrated to be decreased in uremic patients on hemo-
dialysis (HD) and continuous ambulatory peritoneal dialysis
(CAPD) [20]. We have previously found that the in vivo clearance
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of LDL is frequently decreased in uremic patients on conservative
management [21]. No previous studies have assessed the clear-
ance of LDL in uremic patients on either hemodialysis or CAPD
treatment. Therefore, the purpose of this study was to examine
the in vivo clearance of LDL in uremic patients on hemodialysis
and continuous ambulatory peritoneal dialysis. Furthermore, the
resistance of LDL isolated from the uremic patients against
Cu-induced lipid peroxidation was tested.
Methods
Patients and control subjects
Eleven hemodialysis (HD) and nine continuous ambulatory
peritoneal dialysis (CAPD) patients from Oulu University Central
Hospital volunteered for the study (Table 1). The hemodialysis
patients were treated three times weekly (from 9 to 14 hours)
using a single-pass technique and bicarbonate buffered dialysate.
The type of dialysis membrane used was either modified cellulosic
membrane (cellulose-acetate and hemophan) or synthetic poly-
mer membrane, Low molecular weight heparin (Fragmin®, Kabi
Pharmacia, Sweden) was used instead of conventional heparin.
CAPD was performed with four to five daily exchanges (1500 to
2000 ml) using different dextrose concentrations (Dianeal®, Bax-
ter, Round Lake, IL, USA), depending on the need to remove
excess fluid. Patients with a nephrotic syndrome, diabetes mclii-
tus, liver disease or thyroid dysfunction were excluded. One of the
CAPD patients (No. 18) had an acute peritonitis during the LDL
injection study. The patients gave informed consent for the
investigations, and the study was approved by the Ethical Com-
mittee of the Oulu University Medical Faculty.
The control group consisted of nine (2 female and 7 male)
healthy volunteers with the age of 55 20 years (mean SD). The
control group was the same as in our previous work [211.
LDL clearance study had been previously assessed on two
hemodialysis patients (Nos. 1 and 11) and three CAPD patients
(Nos. 12, 13 and 18) while the patients were still on conservative
treatment. One patient participated the LDL clearance study first
when on CAPD treatment (No. 17) and then when on hemodial-
ysis treatment (No. 8).
LDL isolation
Fasting blood samples were drawn into sterile EDTA-contain-
ing tubes, and plasma was separated by centrifugation. The blood
samples from the hemodialysis patients were collected immedi-
ately before the dialysis sessions. LDL (d = 1.019 — 1.063 g/ml)
was isolated by repeated ultracentrifugations [22] using sterile
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Table 1. ClinicaI characteristics of the hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients
Serum Serum
BMI° Serum urea creatinine albumin Duration of
Age Sex kglm2 mmol/liter unol/liter glliter dialysis Diagnosis Drug therapy'
HD
1 33 M 24.0 27.2 1254 41.8 12 months interstitial nephritis furosemide, warfarin, enalapril,
diltiazem, metoprolol, omepratsol,
minoxidil
2 69 F 27.3 9.1 662 34.9 9 years polycystic kidney metoprolol, isosorbide-5-mononitrate,
aspirin, digoxin
3 65 M 30.3 19.1 804 37.0 5 years chr. glomerulonephritis isosobide-5-mononitrate, warfarin
4 52 F 23.7 10.5 728 34.8 18 years chr. pyelonephritis isosorbide dinitrate, aspirin, verapamil,
metoclopramide
5 67 M 21.6 18.7 859 38.6 5 years polycystic kidney metoprolol, aspirin, diltiazem, minoxidil
6 57 M 25.4 20.2 777 42.7 5 years chr. glomerulonephritis isosorbide-5-mononitrate, sotalol,
minoxidil, nifedipine
7 49 M 22.7 17.9 739 36.3 5 months chr. glomerulonephritis atenolol, ditiazem, enalapril,
furosemide
8° 37 F 23.3 15.1 737 34.9 4 months chr. glomerulonephritis captopril, atenolol, nifedipine,
clonidinehydrochloride
9 56 M 22.6 19.9 986 34.9 6 years polycystic kidney aspirin
10 74 M 22.1 20.4 916 42.7 4 years chr. glomerulonephritis acetylsalicylic acid, metoprolol,
isosorbide-5-mononitrate
11 49 M 30.1 22.9 1078 32.5 4 months chr. glomerulonephritis metoprolol, minoxidil, furosemide,
aspirin
mean 58 24.8 18.3 867 37.4 5.4 years
SD 12 3.1 5.3 178 3.6 5.2
CAPD
12 66 F 23.2 18.6 685 31.6 23 months nephrosclerosis diltiazem, captopril, furosemide
13 63 F 19.9 24.3 487 23.6 7 months interstitial nephritis prednisolone, furosemide, sotalol,
isosorbide-5-mononitrate, digoxin
14 46 F 22.5 18.8 731 34.4 13 months polycystic kidney minoxidil, nifedipine
15 47 M 19.9 20.6 1237 39.2 10 months interstitial nephritis allopurinol, felodipine
16 69 F 22.8 23.4 866 31.6 10 months nephrectomy (renal
carcinoma)
nifedipine, captopril
17' 35 F 23.7 25.7 805 26.1 12 months chr. glomerulonephritis captopril, nifedipine, atenolol
18 66 M 27.7 21.0 931 30.7 16 months chr. glomerulonephritis warfarin, sotalol, theophylline
19 75 F 32.8 19.2 1163 26.0 6 years chr. glomerulonephritis atenolol, isosorbide-5-mononitrate
20 59 F 21.8 14.0 448 27.7 7 months polycystic kidney furosemide, isosorbide-5-mononitratc,
digoxin, metoprolol, enalapril
mean 59 24.3 20.6 817 30.1 19 months
13 3.5 270 4.8 21
a Body mass index
b Drugs other than phosphate-binding drugs, vitamins and bicarbonate
C Same patient
techniques. The density of plasma was adjusted to 1.019 g/ml with
sterile NaC1-NaBr solution, and the preparation was ultracentri-
fuged on a fixed angle rotor (Beckman 60 Ti rotor and Beckman
L8-60M ultracentrifuge, Beckman Instruments, Inc., Palo Alto,
CA, USA) at 247000 X g for 18 hours (+ 15°C). The VLDL and
IDL containing fraction (d < 1.019 gIml) was removed by tube
slicing, and LDL was separated from the remaining infranatant by
adjusting the density to 1.063 glml and ultracentrifuging as
described above. Finally, the LDL was washed in NaCl-NaBr
solution (density 1.070 gIml) 114000 X g in a fixed angle rotor
(TFT 40.3 rotor, Kontron Instruments, Zurich, Switzerland) for
18 hours (+ 15°C). Before further use, the isolated LDL was
dialyzed against 0.15 M NaC1 solution containing 0.01% EDTA,
pH 7.4 (EDTA-saline).
lodination of LDL
In the uremic patients nine of the LDL preparations were
iodinated with iodine-131 (1311) and eleven with iodine-125 (125!)
using the iodine monochloride method of McFarlane [23] as
modified by Bilheimer et al [14]. The LDL of the control subjects
was iodinated with 125J Free radioiodine was removed with
column chromatography (Pharmacia Columns PD-b Sephadex
G-25M, Pharmacia, Uppsala, Sweden) and EDTA-saline dialysis.
Precipitation with 10% trichloroacetic acid (TCA) showed that
99.3 2.4% (mean SD) of the 131! counts and 96.4 2.9% of
the 125! counts were bound to protein. The lipid labeling, as
determined with the method of Foich et al [24], averaged 9.7
4.1% (mean SD) for ''i and 9.4 4.7% for 125!
Preparation of LDL for in vivo injection
Radiolabeled LDL preparations were centrifuged at 3300 X g
for 10 minutes (+4°C) and the supernatant was passed through a
0.22 jim Millipore filter. 10 to 20 jiCi of each preparation was
mixed together with 5% human serum albumin (Finnish Red
Cross, Helsinki, Finland) and the final solution was again passed
through a 0.22 jim Millipore filter. The patients were given
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potassium iodide 200 mg/day orally one day before and through-
out the experiment to block the uptake of radioactive iodine by
the thyroid gland.
Study protocol and sample analysis
The preparations containing radiolabeled LDL were injected
intravenously into the uremic patients after an overnight fast. The
injection into the hemodialysis patients was performed between
the dialysis days (24 hr before the next dialysis session and 24 or
48 hr after the preceding session). The CAPD patients continued
with their dialysis schedule normally throughout the experiment.
After the injection, 10 to 20 ml blood samples were obtained at 0,
15, 30 minutes and 1, 2, 3 hours and three times a week for two
weeks after the injection. The blood samples from the hemodial-
ysis patients were always collected immediately before the dialysis
sessions. The total plasma radioactivity was determined in each
sample.
Calculation of the clearance and production rates for LDL
apolipoprotein B
The clearance rate for LDL (the fractional catabolic rate, FCR,
defined as the intravascular pool of LDL catabolized per hour)
was calculated from the plasma decay curve using the method
described by Matthews [25], Nosslin [26] and Langer, Strober and
Levy [27]. In this method two exponential equations were fitted
into each plasma and LDL fraction decay curve with a curve-
peeling program (W.F. Beltz and T.E. Carew, unpublished
method) on a VAX-VMS computer. The LDL apolipoprotein B
(LDL apoB) production rates were calculated from the fractional
catabolic rates for LDL, pool volumes and apolipoprotein B
concentrations, and expressed as milligrams per kilogram of body
weight per day. We have previously tested the reproducibility of
the LDL clearance method [21].
Venfication of the plasma radioactivity method for the calculation
of the LDL clearance rates
To ensure that the measured radiolabel remained in the
isolated LDL density range LDL, fractions from all plasma
samples were isolated by repeated ultracentrifugations. The iso-
lated LDL fractions were dialyzed in EDTA-saline and the
radioactivities were determined. A total of 92.7 2.0% of the
LDL in hemodialysis patients (N = 8, Nos. 2 to 5 and 8 to 10) and
92.6 1.7% of the LDL in CAPD patients (N = 6, Nos. 12 to 17)
in all the fractions up to 14 days fiotated within the originally
isolated LDL density region.
The clearance rates for LDL were calculated from the isolated
LDL fraction decay curves as described above. The FCRs ob-
tained from the LDL fraction decay curves were slightly higher
than those obtained from the plasma decay curves (by 9.1 5.3%
in the hemodialysis patients and by 5.3 5.0% in the CAPD
patients). Since there was only a minor difference between the
FCR values obtained from the LDL fraction and the plasma decay
curves, and since the FCRs of the control subjects were calculated
from the plasma decay curves, the FCRs calculated from the
plasma decay curves are also reported for the uremic patients.
Lipoprotein fractionation for lipoprotein analysis
Various lipoprotein fractions were isolated from the plasma
samples of the patients and the control subjects by repeated
ultracentrifugations [211 using appropriate density adjustments
with NaCI-NaBr solutions and the fixed angle TFF rotor at 114000
x g (+ 15°C) for 18 hours (VLDL, IDL and LDL fractions) and
for 48 hours (HDL fraction). To correct the lipoprotein losses in
the LDL and HDL fractions during the sequential ultracentrifu-
gations, the VLDL fraction was first isolated from a separate
simultaneous plasma sample as described above and HDL cho-
lesterol was measured from the remaining infranatant (VLDL-
infranatant) after precipitation of IDL and LDL with heparin-
manganese [28]. LDL cholesterol was calculated by subtracting
the HDL and IDL cholesterol from the total cholesterol content
of the VLDL-infranatant. The cholesterol, triglyceride and pro-
tein concentrations in the LDL and HDL fractions were then
corrected by the ratio of the LDL (or HDL) cholesterol concen-
tration measured with heparin-manganese precipitation to the
LDL (or HDL) cholesterol concentration measured after re-
peated ultracentrifugations.
Lipid and protein analysis
The cholesterol and triglyceride concentrations were deter-
mined with Specific Selective Chemistry Analyzer (Kone, Finland)
using enzymatic colorimetric methods (kits of Boehringer Diag-
nostica, Mannheim GmbH, Germany; catalog nos. 236691 and
701912, respectively). The protein contents of the various lipopro-
tein fractions were measured with the method of Lowry et al [29]
and the amount of apolipoprotein B was determined after isopro-
panol precipitation [30]. Lipid and protein values for each patient
were calculated as the mean value of determination of three
separate samples taken on different days during the LDL clear-
ance study.
Lipid peroxidation assays
The propensity for oxidation of LDL isolated from the uremic
patients was tested as the formation of conjugated dienes [31] and
TBARS [32]. The control LDL (LDL isolated from control
subject No. 2) was isolated and tested for oxidation each time
simultaneously with the uremic LDL. After isolation the LDL
preparations were extensively dialysed against phosphate buffered
saline for 24 hours to remove EDTA. The formation of conju-
gated dienes was measured by incubating LDL (100 g/ml of LDL
protein) in a quartz cuvette with 5 j.LM Cu (room temperature)
and recording the change of 234 nm absorption in a UV-
spectrophotometer (Shimadzu UV-160A Recording Spectropho-
tometer, Shimadzu Corp., Kyoto, Japan) [311. The oxidation
resistance was defined as the length of the lag-phase time (the
intercept with the x-axis) and the maximal rate of oxidation (the
slope of the absorbance curve during the propagation phase
expressed as the change in absorbance per hour) [321. The
TBARS were measured from the LDL preparations (100 jLg/ml of
LDL protein) oxidized for four hours with 5 iii Cu+ [31].
Urea and creatinine analysis
The serum urea and creatinine concentrations were determined
with standard methods in the routine laboratory of the Oulu
University Central Hospital.
Statistical analysis
The statistical significances of the results were calculated using
Student's i-test and the coefficients of correlation (Pearson) were
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Table 2. Plasma and lipoprotein lipids in the hemodialysis patients
(HD), Continuous ambulatory peritoneal dialysis patients (CAPD) and
control subjects
HD P CAPD P Controls
Total-CHOL 4.52
(0.76)
<0.OO1C 6.59
(1.53)
001b 4.82
(1.08)
VLDL-CHOL 0.69 0.Ola 1.05 0.41
IDL-CHOL
(0.19)
0.35
(0.15)
0.002a
(1.05)
0.49
(0.18)
<0001b
(0.24)
0.15
(0.07)
LDL-CHOL 2.26
(0.60)
0.03c 3.33
(1.40)
2.66
(0.81)
HDL-CHOL 0.92 <0.OOla 1.12 1.44
Total-TG
(0.12)
1.76
(0.69)
0.OP
(0.53)
2.63
(2.15)
004b
(0.28)
0.99
(0.30)
VLDL-TG 0.96 0.Ola 1.37 0.45
IDL-TG
(0.53)
0.11 0.02a
(1.36)
0.18 <0001b
(0.19)
0.07
LDL-TG
(0.04)
0.28
0.003c
0.002'
(0.05)
0.47 O.Ol
(0.03)
0.27
HDL-TG
(0.06)
0.19
(0.08)
0.009c
(0.16)
0.39
(0.21)
0005b
(0.13)
0.15
(0.06)
Data are mean (so).
Abbreviations are CHOL, cholesterol; TG, triglyceride.
a HD patients versus control subjects
b CAPD patients versus control subjects
HD patients versus CAPD patients
analyzed with linear regression analysis. Data are presented as
means SD.
Results
Plasma lipids and lipoproteins
The total cholesterol and triglyceride concentrations in the
plasma and different lipoprotein fractions of the uremic patients
and the control subjects are shown in Table 2. The HD patients
had markedly increased VLDL and IDL cholesterol concentra-
tions and decreased HDL cholesterol concentration in compari-
son to the control subjects (Table 2). The plasma total and LDL
cholesterol concentrations of the HD patients were significantly
lower than those of the CAPD patients. The HD patients had
markedly higher plasma total, VLDL and IDL triglyceride con-
centrations than the control subjects. In addition, the IDL, LDL
and HDL triglyceride levels of the HD patients were markedly
lower than those of the CAPD patients (Table 2). The CAPD
patients had markedly increased plasma total and IDL cholesterol
concentrations and plasma total, IDL, LDL and HDL triglyceride
concentrations in comparison with the control subjects (Table 2).
Clearance and production of LDL apolipoprotein B
The clearance rates (fractional catabolic rate, FCR) and the
production rates and concentrations of LDL apolipoprotein B for
the uremic patients and the control subjects are shown in Table 3.
The clearance of LDL in all uremic patients (FCR for LDL 0.305
0.075 pools/day) was significantly lower than the clearance of
LDL in the control subjects (P = 0.01; Table 3). The LDL
clearance rates of the HD patients (FCR for LDL 0.334 0.066
pools/day) did not differ significantly from those of the control
subjects (FCR for LDL 0.376 0.045 pools/day, P = 0.122).
However, the clearance rates for LDL in the CAPD patients
Table 3. Clearance and production rates and concentrations of LDL
apolipoprotein B in the uremic patients and the control subjects
FCR for LDL
pools/day
LDLap0B
production
mg/kg/day
LDL
ApoB A
mg/dl
LDL
poB:CHOL
ratio
LOL
CHOL:TG
ratio
HD
1
2
3
4
5
6
7
8
9
10
11
0.274
0.294
0.294
0.296
0.299
0.302
0.316
0.334
0.347
0.451
0.472
9
9
6
7
8
8
16
11
11
8
8
42
78
54
55
63
47
66
67
72
40
43
0.71
0.64
0.63
0.53
0.70
0.40
0.66
0.70
0.59
0.78
0.65
3.00
5.69
2.74
4.71
3.45
2.89
3.51
2.58
5.23
2.63
3.32
CAPD
12
13
14
15
16
17
18
19
20
mean
so
p
0.188
0.212
0.216
0.217
0.227
0.292
0.325
0.339
0.397
0.305
o.ola
5
7
9
9
7
11
6
3
12
8
o.oo3a
57
85
78
102
71
73
33
29
77
62
0.60
0.46
0.57
0.34
0.41
0.54
0.14
0.47
1.27
0.59
4.49
5.73
4.09
4.66
4.57
2.25
1.37
2.83
0.78
3.53
1.
2.
3.
4.
5.
6.
7.
8.
9.
mean
SD
0.318
0.319
0.347
0.360
0.366
0.386
0.412
0.435
0.437
0.376
9
10
15
11
13
14
14
7
12
12
45
60
84
68
100
99
56
32
53
66
0.47
0.39
0.68
0.49
0.80
0.69
0.60
0.75
0.52
0.60
5.75
5.96
3.60
4.52
6.38
4.20
4.67
3.00
7.65
5.08
Abbreviation FCR is fractional catabolic rate.
a HD and CAPD patients versus control subjects
(FCR for LDL 0.267 0.072 pools/day) were markedly lower
compared to the control subjects (P = 0.001) and to the HD
patients (P = 0.04).
The LDL apoB production rates of uremic patients (8 3
mg/kg/day) were markedly lower (P = 0.003) than those of the
control subjects (12 3 mg/kg/day; Table 3). The LDL apoB
production rates of both the HD patients (9 3 mg/kg/day) and
the CAPD patients (8 3 mg/kg/day) were significantly lower
than those of the control subjects (P = 0.04 and P = 0.01 for HD
and CAPD patients, respectively). The LDL apolipoprotein B
concentrations and the LDL apoB:cholesterol ratios of the uremic
patients did not significantly differ from those of the control
subjects (Table 3). The LDL cholesterol:triglyceride ratios of the
uremic patients (3.53 1.35) were markedly lower than those of
the control subjects (5.08 1.47, P = 0.01; Table 3).
The clearance rate of LDL in all the uremic patients was
negatively related to the plasma total cholesterol concentration (r
=
—0.57, P = 0.01) and LDL cholesterol concentration (r =
—0.77, P = 0.0001) and to the LDL apoB concentration (r =
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—0.48, P = 0.03; Fig. 1). In addition, the clearance rate of LDL
was negatively related to the LDL cholesterol:triglyceride ratio
(Fig. 1). The LDL apoB production rates, however, were not
related to any plasma total or lipoprotein lipid values. Also, no
relation was found between the clearance rate for LDL and serum
albumin levels of the patients (r = 0.11, P = 0.64). Although the
mean duration time of dialysis of the hemodialysis patients was
longer (5.4 5.2 years) than that of the CAPD patients (19 21
months), no relation was found between the clearance rate for
LDL and the duration time of dialysis (r =0.05, P = 0.84) among
all the uremic patients.
LDL clearance and plasma lipids and lipoproteins before and
after hemodialysis and CAPD treatment
Table 4 shows the LDL clearance and plasma lipids and
lipoproteins of five patients on conservative treatment and after
the beginning of either hemodialysis treatment (patient Nos. 1
and 11) or CAPD treatment (Nos. 12, 13 and 18). Patient No. 18
had an acute peritonitis during the LDL injection study. The
clearance of LDL in one patient was first studied when the patient
was on CAPD treatment (No. 17) and then when the patient was
on hemodialysis treatment (No. 8; Table 4).
A decrease was observed in the LDL cholesterol concentration
after the beginning of the hemodialysis treatment in patient Nos.
1 and 11 (Table 4). The clearance of LDL was not significantly
altered after the beginning of the hemodialysis treatment (Fig. 2).
LDL cholesterol concentration was increased in patient Nos. 12
and 13 and decreased in patient No. 18 after the beginning of the
6 CAPD treatment (Table 4). The FCR for LDL in patient No. 12
had decreased from 0.211 to 0.188 pools/day and in patient No. 13
from 0.367 to 0.212 pools/day after the beginning of the CAPD
therapy (Fig. 2). The FCR for LDL in patient No. 18 had
increased from 0.216 to 0.325 pools/day (Fig. 2).
LDL cholesterol concentration of the patient No. 17 (on CAPD1 treatment) had decreased after the beginning of the HD treat-
2 ment (No. 8; Table 4). The clearance rate for LDL was increased
by from 0.292 pools/day on CAPD treatment to 0.334 pools/day on
HD treatment (Fig. 2).
Lipid peroxidation assays
6 No significant differences were observed in the oxidation resis-
tance between uremic and control LDL, when the oxidation was
B estimated as the thiobarbituric acid-reacting substances (TBARS),
r- the lag-phase time and the rate of oxidation (Fig. 3). Also no
significant differences were found between the uremic patients on
hemodialysis and CAPD treatments. The LDL of the hemodial-
-1 .
ysis patients contained 1.4 5.4 nmol MDA/mg protein (N 8)2 and the LDL of the CAPD patients contained 3.8 12.8 nmol
5' MDA/mg protein (N = 8) more thiobarbituric acid-reacting
substances relative to control LDL. The lag-phase time of LDL of
0 the hemodialysis patients was 7,9 39.1 mm (N = 8) longer and
of the CAPD patients was 7.7 8.0 mm (N = 8) shorter relative
to control LDL. Overall, in the uremic patients the lag-phase time
of LDL was related to the LDL triglyceride concentration (r =
—0.57, P = 0.03) and to the serum urea concentrations of the
patients (r = —0.82, P = 0.004).
Discussion
The major finding of this study was that the clearance of LDL
is decreased in uremic patients on dialysis treatment. This was
particularly observed in the uremic patients on CAPD treatment.
We have previously demonstrated that the clearance rates of
LDL are lower than normal in patients with chronic renal failure
on conservative management, varying from 0.146 to 0.416 pools/
day (mean 0.307 pools/day) and being negatively related to the
serum urea concentration (r =
—0.62, P = 0.02) [213. In the
present study the fractional catabolic rates for LDL in the uremic
patients on hemodialysis and continuous ambulatory peritoneal
dialysis (0.305 0.075 pools/day) were markedly lower than the
FCRs of our control subjects (0.376 0.045 pools/day) and the
FCRs documented for normal subjects in the literature (from
0.287 and 0.462 pools/day, mean 0.371 pools/day) [15]. The FCRs
for LDL in the hemodialysis patients (0.334 0.066 pools/day)
were only mildly decreased compared to our control subjects. On
the other hand, the clearance rates for LDL in the CAPD patients
(0.267 0.072 pools/day) were markedly decreased compared to
our control subjects. An important finding was that the clearance
rates for LDL in five CAPD patients (Nos. 12 to 16) were
extremely low (from 0.188 to 0.227 pools/day). Such low FCRs are
usually observed in patients with heterozygous (0.237 0.044
pools/day) and homozygous (0.176 0.040 pools/day) familial
hypercholesterolemia (FH) [13—15]. FH patients, however, have
genetic defects in the LDL receptor gene, and therefore the
mature receptors can neither bind nor internalize LDL particles.
The CAPD patients, however, had no clinical signs of FH, and
their LDL cholesterol concentrations were only marginally in-
creased (from 3.35 to 4.79 mmol/liter). Moreover, on patient with
extremely low FCR (No. 13, FCR = 0.212 pools/day) had
r=—0.57, P=0.008 r=—0.77, P=0.0001
0
10
L
0
E
E
0
120
II)
E80
E
0
o 40
-Ja
-J
0
0.2 0.3 0.4 0.5 0.2 0.3 0.4 0.5
FCR, pools/day
Fig. 1. Relationship between the fractional catabolic rate (FCR) for LDL
and the plasma total and LDL cholesterol concentrations, LDL apolipopro-
tein B concentration and LDL cholesterol.triglyceride ratios in the hemodi-
alysis (•) and the CAPD (0) patients. Abbreviations are: CHOL, choles-
terol; TG, triglycerides.
0
0
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Table 4. Plasma lipids and lipoproteins and LDL apolipoprotein clearance and production rates of two hemodialysis (HD) and three CAPD
patients on conservative treatment (CON) and after the beginning of the dialysis treatment, and of one patient on both HD and CAPD treatments
N
CON
o. 1
HD
No.
CON
11
HD
N
CON
o. 12
CAPD
No.
CON
13
CAPD CON
No. 18
CAPD
No 17
CAPD'
No 8
HDb
Weight kg 68 77 85 84 58 58 51 49 72 82 66 65
Serum urea mmol/liter 19.1 27.2 27.1 22.9 28.0 18.6 25.2 24.3 25.3 21.0 25.7 15.1
Serum creatinine pmol/liter 551 1254 1302 1078 1132 685 634 487 993 931 805 737
GFR ml/min/1.73 m2 9.2 11.5 13.6 13.5 10.2
Cholesterol mmol/liter
Plasma total 3.58 3.54 4.26 3.89 6.70 7.69 4.85 7.94 3.72 3.72 6.55 5.11
VLDL 0.42 0.65 0.70 0.61 0.79 0.46 0.42 0.77 0.53 1.14 0.89 0.79
IDL 0.19 0.24 0.40 0.35 0.25 0.34 0.47 0.56 0.20 0.24 0.54 0.50
LDL 1.70 1.55 1.92 1.73 3.61 4.39 2.49 4.79 1.90 1.50 3.52 2.50
HDL 0.98 0.78 1.10 0.94 1.82 2.24 1.38 1.27 0.66 0.43 0.98 0.77
Triglycerides mmol/liter
Plasma total 1.17 1.28 1.42 1.47 1.86 1.71 0.98 2.03 2.05 3.18 2.09 1.84
VLDL 0.53 0.66 0.57 0.78 0.98 0.76 0.14 0.99 0.91 2.02 0.91 0.78
IDL 0.05 0.06 0.07 0.10 0.11 0.14 0.01 0.17 0.07 0.21 0.24 0.16
LDL 0.16 0.23 0.25 0.23 0.37 0.41 0.24 0.37 0.41 0.50 0.71 0.42
HDL 0.15 0.14 0.22 0.15 0.24 0.60 0.14 0.14 0.23 0.21 0.31 0.42
FCR for LDL pools/day 0.282 0.274 0.435 0.472 0.211 0.188 0.367 0.212 0.216 0.325 0.292 0.334
LDL apoB
production mg/kg/day 7 9 16 8 20 5 16 7 7 8 11 11
LDL ApoB mg/dl 39 42 77 43 135 57 65 85 50 33 73 67
LDL CHOL:TG ratio 4.71 3.00 3.53 3.32 4.36 4.49 4.49 5.73 2.07 1.37 2.25 2.58
LDL ApoB:CHOL ratio 0.57 0.71 0.99 0.65 0.96 0.60 0.70 0.46 0.68 0.79 0.54 0.64
a Peritonitis during the LDL injection studybSame patient
previously had normal LDL clearance while on conservative
management (FCR = 0.367 pools/day). It can therefore be
concluded, that the CAPD patients with low LDL clearance rates
did not have familial hypercholesterolemia. The clearance rates
for LDL in the four remaining CAPD patients (Nos. 17 to 20)
were quite normal (from 0.292 to 0.397 pools/day).
There are several possible mechanisms for the decrease of LDL
clearance observed in the uremic patients of the present study.
First, the LDL particles isolated from the patients may have been
altered in such a way that they cannot bind to LDL apoB/E
receptors. This would not be surprising, since it has already been
demonstrated that LDL isolated from uremic patients [19] and
from uremic guinea pigs [18] shows decreased clearance in vivo.
Such an alteration in the LDL particles could be a chemical
modification of the LDL apolipoprotein B, such as with carbamyl
groups, since carbamylated LDL shows decreased clearance in
vivo [19] and decreased binding to the LDL apoB/E receptors [19,
33, 34]. Also, it has recently been shown that patients with
end-stage renal disease have high concentrations of advanced
glycosylation endproducts (AGE) in tissue and plasma [35, 36]
and that serum AGE levels correlate inversely with renal function
[37]. Normally, the formation of AGEs is important for proteins
with long half-lives, such as collagen [38]. But, under conditions of
high sugar or AGE concentrations, such as diabetes mellitus or
chronic renal failure, the formation of AGEs may also affect
proteins with short half-lives, including LDL apolipoprotein B.
Finally, an abnormal chemical composition of the LDL isolated
from the uremic patients might alter the LDL clearance. It has
been documented that the triglyceride content in the core of the
LDL particles has some influence on the conformation of
the LDL receptor binding domain [12] and that the triglyceride-
rich LDL is catabolized poorly in human fibroblasts [9—11]. The
LDL of both hemodialysis and CAPD patients was triglyceride-
rich in comparison with that of the control subjects. Interestingly,
the clearance rates for LDL were negatively related to the LDL
cholesterol:triglyceride ratios (that is, the more the LDL con-
tained triglycerides in relation to cholesterol the faster it was
cleared from the circulation).
A second explanation for the low LDL clearance observed in
the uremic patients might be that there are alterations in the LDL
receptors. It was recently demonstrated that the LDL apoB/E
receptor function and the mRNA expression are lower than
normal in the lymphocytes isolated from uremic patients [39]. The
level of dysfunction was also similar to that seen in patients with
FH. The results of the study suggest that there are fewer LDL
receptors than normally in uremic patients, which is due to either
a transcriptional defect, reduced LDL receptor mRNA stability,
or increased LDL receptor mRNA degradation [39]. Our results
are in good agreement with the findings on a receptor function
defect [39], except that the latter study showed no correlation
between the lymphocyte LDL receptor dysfunction or mRNA
levels and serum lipid and lipoproteins. The LDL clearance rates
in our study, however, showed a close relationship with the plasma
total and LDL cholesterol and LDL apoB concentrations. This
could be one explanation to the previous findings that patients on
CAPD treatment have higher plasma and LDL cholesterol and
apolipoprotein B levels than patients on hemodialysis treatment
[40, 41].
At any rate, the LDL-receptor related mechanism could explain
the decreased LDL clearance in our uremic patients on dialysis
treatment. Another LDL receptor-related mechanism possibly
causing decreased LDL clearance in the patients of the present
study might be that the LDL receptors, rather than the LDL
A TBARS, B Lag-phase, minutes C Rate of oxidation,
nmol/MDNmg protein change in absorbanceMr
a)
C)
a)
a)(I)0
0
C0
C)
CU
Li..
particles, are post-translationally modified, for example, carbamy-
lated or AGE-modified. This mechanism has not been explored.
Our previous study concluded that the apolipoprotein B pro-
duction was normal despite the decreased clearance of LDL in
uremic patients on conservative management (12 4 mg/kg/day)
[21]. However, the LDL apolipoprotein B production rates for the
hemodialysis (9 3 mg/kg/day) and CAPD patients (8 3
mg/kg/day) were markedly lower than those for the control
subjects (12 3 mg/kg/day) or those documented for normal
subjects in the literature (mean 11.4 mg/kg/day) [15]. It is surprising
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Fig. 2. Plasma decay curves for LDL in five uremic patients on conservative treatment (0) and after the beginning of either hemodialysis treatment (U, Nos.
1 and 11) or CAPD treatment (A; Nos. 12, 13 and 18), and of one uremic patient on hemodialysis (No. 8) and on CAPD (No. 17) treatment.
Fig. 3. The resistance of the uremic LDL ') and control LDL (U) against Cu oxidation measured as the thiobarbituric acid-reacting substances (TBARS)
and formation of conjugated dienes (lag-phase time and rate of oxidation).
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that CAPD patients with such low LDL clearance rates also have
low LDL apolipoprotein B production rates. Moreover, the LDL
apolipoprotein B concentrations were similar (62 19 mgldl) in
comparison with the control subjects (66 24 mg/dl). In contrast,
however, low LDL clearance is associated with a much higher
LDL apoB production rates and apolipoprotein B concentrations
in heterozygous (13.8 3.6 mg/kg/day and 126 21 mg/dl, LDL
apoB production rate and concentration, respectively) and partic-
ularly homozygous FH patients (26.4 10.0 mg/kg/day and 362
126 mg/dl) [15]. Overall, these findings suggest that the low LDL
production rates also contribute to the regulation of the LDL
cholesterol concentrations in uremic patients, and that the LDL
cholesterol levels in uremic patients with low LDL clearance rates
therefore remain normal or only increase slightly.
It has been suggested that LDL lipid peroxidation is involved in
the development of atherosclerosis [421. A previous study showed
that uremic patients on hemodialysis had increased plasma total
lipid peroxidation and decreased serum antioxidant activity [43].
Moreover, the amount of thiobarbituric acid reacting substances
on freshly isolated VLDL, but not LDL or HDL, has been
documented to be significantly higher in hemodialysis patients
than in controls [44]. Despite this, we observed no marked
differences in the resistance against Cu oxidation between the
uremic patients' own LDL and LDL isolated from the control
subject. This is in agreement with a recent study demonstrating
that plasma lipids are not oxidized during hemodialysis treatment
[45]. On the other hand, it was interesting to note that the
lag-phase time of the LDL isolated from the uremic patients was
closely related to the patients' serum urea concentration (r =
—0.82, P = 0.004). The negative relation between the lag-phase
time of the LDL and the LDL triglyceride concentration (r =
—0.57, P = 0.03) is in a good agreement with the previous finding
that triglyceride-rich lipoproteins have an increased rate of oxi-
dation [46].
In conclusion, we have demonstrated that LDL clearance is
decreased in uremic patients on dialysis treatment. The clearance
of LDL is only mildly decreased in uremic patients on hemodial-
ysis treatment and markedly decreased in patients on CAPD
treatment. The cause for the extremely low LDL clearance in
some uremic patients remains to be explored. Further studies are
needed to reveal the impact of the type of dialysis (that is,
hemodialysis and CAPD) on LDL metabolism. CAPD is such a
new type of treatment in comparison with hemodialysis that
studies comparing prevalence and course of coronary artery
disease on CAPD with those on hemodialysis are lacking [47]. Dc
nova appearance of ischemic heart disease was seen in 9% of
CAPD patients after one year and in 15% after two years of
treatment [48]. In a different study on hemodialysis patients these
values were 12 and 18%, respectively [49]. It should be remem-
bered that, theoretically, CAPD might have a negative effect on
coronary artery disease due to hyperlipidemia, which is more
frequent on this method than on hemodialysis [47]. In any case,
the delayed LDL clearance in the uremic patients, observed in the
present study, results in an increase of the residence time of LDL
in the circulation, which may lead to further disturbances of LDL
metabolism, for example, carbamylation, oxidation, or interaction
with glycosaminoglycans, which have been suggested to accelerate
atherosclerosis [19, 50, 51].
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